SCHEMBL19089460

SCHEMBL19089460

CCCCCCCCOP(=O)(OC)OCC[N+](C)(C)C

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.68
AKT1 P31749 2/20 0.68
ESR1 P03372 1/20 0.68
ADORA3 P0DMS8 1/20 0.68
CDC25A P30304 1/20 0.68
AGTR1 P30556 1/20 0.68
ADRA1A P35348 1/20 0.68
KCNH2 Q12809 1/20 0.68
PRKD3 O94806 2/20 0.52
PRKCG P05129 2/20 0.52
PRKCB P05771 2/20 0.52
PRKCA P17252 2/20 0.52
PRKCH P24723 2/20 0.52
PRKCI P41743 2/20 0.52
PRKCE Q02156 2/20 0.52
PRKCQ Q04759 2/20 0.52
PRKCZ Q05513 2/20 0.52
PRKCD Q05655 2/20 0.52
PRKD1 Q15139 2/20 0.52
ALDH1A1 P00352 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18970789 1.00 LMNA (0.68) LMNAAKT1ESR1ADORA3CDC25A
SCHEMBL19089198 1.00 LMNA (0.68) LMNAAKT1ESR1ADORA3CDC25A
SCHEMBL23016765 1.00 LMNA (0.68) LMNAAKT1ESR1ADORA3CDC25A
SCHEMBL17817230 0.93 LMNA (0.58) LMNAAKT1ESR1ADORA3CDC25A
SCHEMBL23016751 0.93 LMNA (0.58) LMNAAKT1ESR1ADORA3CDC25A
SCHEMBL17817502 0.93 CYP3A4 (0.57) LMNAAKT1ESR1ADORA3CDC25A
SCHEMBL17817441 0.93 LMNA (0.56) LMNAAKT1ESR1ADORA3CDC25A
SCHEMBL5822144 0.91 LMNA (0.74) LMNAAKT1ESR1ADORA3CDC25A
SCHEMBL29060954 0.91 LMNA (0.74) LMNAAKT1ESR1ADORA3CDC25A
SCHEMBL22721395 0.91 LMNA (0.74) LMNAAKT1ESR1ADORA3CDC25A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11584790-B2 Complement factor D antagonist antibodies and conjugates thereof KODIAK SCIENCES INC. (US) 2023-02-21 US disclosed
US-11066465-B2 Antibodies and conjugates thereof KODIAK SCIENCES INC. (US) 2021-07-20 US disclosed
US-20170190766-A1 ANTIBODIES AND CONJUGATES THEREOF KODIAK SCIENCES INC. 2017-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170190766-A1 ANTIBODIES AND CONJUGATES THEREOF VEGFA, FLT1, HDGF LMNA 1554/4885AKT1 1258/4885ESR1 2978/4885
US-11066465-B2 Antibodies and conjugates thereof VEGFA, FLT1, HDGF LMNA 1554/4885AKT1 1258/4885ESR1 2978/4885
US-11584790-B2 Complement factor D antagonist antibodies and conjugates thereof CFD, CFH, CFB LMNA 2180/4885AKT1 3750/4885ESR1 2718/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.